Company Overview of Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc. develops and markets pharmaceutical products. The company offers products for central nervous system disorders, such as insomnia, schizophrenia, bipolar depression, and epilepsy disorders; attention deficit hyperactivity and binge-eating disorders; and respiratory conditions, including asthma, allergy, and chronic obstructive pulmonary disease areas. Sunovion Pharmaceuticals Inc. was formerly known as Sepracor Inc. and changed its name to Sunovion Pharmaceuticals Inc. in October 2010. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts. As of October 20, 2009, Sunovion Pharmaceuticals Inc. operates as a subsidiary of Dainippon Sumi...
84 Waterford Drive
Marlborough, MA 01752
Founded in 1984
Key Executives for Sunovion Pharmaceuticals Inc.
Chairman and Chief Executive Officer
Chief Financial Officer and Senior Vice President
Chief Administrative Officer and Executive Vice President
Chief Compliance & Ethics Officer and Senior Vice President
Chief Medical Officer, Executive Vice President and Head of Global Clinical Development
Compensation as of Fiscal Year 2015.
Sunovion Pharmaceuticals Inc. Key Developments
Sunovion Pharmaceuticals Inc. Announces the Results of Brovana® (arformoterol tartrate) Inhalation Solution
May 16 16
Sunovion Pharmaceuticals Inc. announced the results of a post-hoc analysis of a long-term safety study evaluating Brovana® (arformoterol tartrate) Inhalation Solution in people with moderate-to-severe chronic obstructive pulmonary disease (COPD) at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13-18, 2016 in San Francisco, Calif. Results from this analysis reinforce the use of BROVANA in COPD, as measured by COPD exacerbation-related hospitalizations compared to those treated with placebo. BROVANA is a twice-daily nebulized long-acting beta2-agonist (LABA) approved by the U.S. Food and Drug Administration (FDA) for the long-term maintenance treatment of bronchoconstriction in people with COPD, including chronic bronchitis and emphysema. Data for this post hoc analysis came from a multicenter, randomized, double-blind, 52-week safety trial evaluating BROVANA versus placebo in patients with moderate-to-severe COPD. Data on COPD exacerbation and associated hospitalization events were collected in the study. Post-hoc analyses of these data demonstrated that patients receiving BROVANA exhibited lower annualized COPD exacerbation-related hospitalization rates compared with patients receiving placebo. The BROVANA group also reported a greater reduction in hospitalization risk relative to placebo, and these results were more pronounced in a subset of patients who were responders on the St. George’s Respiratory Questionnaire (SGRQ) (i.e., patients who achieved a minimum 4-point improvement in SGRQ total score at study end). The SGRQ is an index designed to measure and quantify health-related health status in patients with chronic airflow limitation that has been shown to correlate well with established measures of symptom level, disease activity and disability.1 For the intent-to-treat population, the adjusted annualized hospitalization rate was significantly reduced with BROVANA compared with placebo (relative risk = 0.60 [95% confidence interval (CI) = 0.41, 0.87; P = 0.007]). For those patients who were SGRQ responders, the adjusted relative risk was the lowest at 0.34 (95% CI = 0.12, 0.99; P = 0.048); SGRQ non-responders had an adjusted relative risk of 0.81 (95% CI = 0.39, 1.67; P = 0.573).
Sunovion Pharmaceuticals Inc. Announces Positive Results from Phase 3 Clinical Trial Program for SUN-101
Apr 27 16
Sunovion Pharmaceuticals Inc. announced positive results from the Phase 3 clinical trial program for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist (LAMA), delivered via PARI’s innovative investigational eFlow® nebulizer system (SUN-101/eFlow®), for people with moderate-to-very severe chronic obstructive pulmonary disease (COPD). The two clinical trials met their primary endpoints with a statistically significant change from baseline in trough forced expiratory volume in one second (FEV1) at Week 12 for both the 50 mcg and 25 mcg dose groups versus placebo. SUN-101/eFlow® also was found to be well-tolerated as a twice-daily maintenance treatment of bronchoconstriction in patients with COPD. SUN-101 (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator delivered via the innovative, proprietary closed investigational eFlow® nebulizer system. SUN-101/eFlow® is currently in development as a nebulized treatment for patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD). The investigational combined product, consisting of SUN-101 and the closed eFlow® nebulizer system which has been optimized for SUN-101 delivery, has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COPD.
PGI Drug Discovery LLC Announces Drug Discovery Collaboration with Sunovion Pharmaceuticals Inc
Apr 4 16
PGI Drug Discovery LLC announced that a compound identified through its drug discovery collaboration with Sunovion Pharmaceuticals Inc. has achieved a milestone. The compound, SEP-856, is a potential antipsychotic agent with a novel mechanism of action being investigated as a possible treatment for patients with schizophrenia. The preclinical models for SEP-856 suggest that it may have the potential to treat the negative symptoms of schizophrenia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|